by admin | Jul 18, 2022 | Bernie Siegel’s WORLD STEM CELL SUMMIT BLOG, News and Opinions
“Algebra, much less “algebraic topology”, was never my strong suit. However, reading this fascinating article definitely stimulated the 11 dimensions in my aging lawyer’s brain! According to a study published in “Frontiers in...
by admin | Jul 15, 2022 | Bernie Siegel’s WORLD STEM CELL SUMMIT BLOG, News and Opinions, Video
By Susan Buckles “The sky’s the limit,” “possibility” and “potential cure for disease” are aspirational ways Mayo Clinic physicians and scientists described regenerative medicine in a recent virtual presentation at the World...
by admin | Jul 14, 2022 | Bernie Siegel’s WORLD STEM CELL SUMMIT BLOG, News and Opinions
By Gail Dutton – Genetic Engineering and Biotechnology News Stemson Therapeutics is harvesting patient cells, generating and differentiating iPSCs, and pro-ducing dermal papilla cells in abundance Hair loss can be distressing, even devastating, but it isn’t...
:format(webp)/cdn.vox-cdn.com/uploads/chorus_image/image/70912912/Image_4.0.jpg "Scientists grow cells on a robot skeleton (but don’t know what to do with them yet)")
by admin | Jul 13, 2022 | Bernie Siegel’s WORLD STEM CELL SUMMIT BLOG, News and Opinions
A new method of tissue engineering is only a proof of concept for now By James Vincent – The Verge The science of tissue engineering — or growing human cells for use in medicine — is very much in its infancy, with only the simplest lab-grown cells able to be...
by admin | Jul 12, 2022 | Bernie Siegel’s WORLD STEM CELL SUMMIT BLOG, News and Opinions
PHILADELPHIA – The U.S. Food and Drug Administration (FDA) has expanded its approval for a personalized cellular therapy developed at the University of Pennsylvania’s Abramson Cancer Center, this time for the treatment of adults with relapsed or refractory follicular...
by admin | Jul 12, 2022 | Bernie Siegel’s WORLD STEM CELL SUMMIT BLOG, News and Opinions
By Jane Byrne BioPharma-Reporter The potential of cell therapy is proven, but its impact is limited by manufacturing bottlenecks. “There is broad consensus that we need to automate and quickly in order for cell therapy manufacturing to become a viable industry,...
